{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:58:38Z","timestamp":1785193118942,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"31","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26K11115"],"award-info":[{"award-number":["26K11115"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06648"],"award-info":[{"award-number":["23K06648"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H03665"],"award-info":[{"award-number":["19H03665"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K27609"],"award-info":[{"award-number":["23K27609"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015642","name":"Japan Lung Cancer Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015642","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002241","name":"MEXT | Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJSP2135"],"award-info":[{"award-number":["JPMJSP2135"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,8,18]]},"DOI":"10.1038\/s41388-026-03877-8","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:55:31Z","timestamp":1783007731000},"page":"3244-3257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C\u2013mutant non-small cell lung cancer"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2963-7265","authenticated-orcid":false,"given":"Yifeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8356-9849","authenticated-orcid":false,"given":"Shigeki","family":"Nanjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2579-8472","authenticated-orcid":false,"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-9558","authenticated-orcid":false,"given":"Hirokazu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8544-6244","authenticated-orcid":false,"given":"Koji","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Koba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Tambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Ohkura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Abo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Hosomichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"3877_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"3877_CR2","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","volume":"18","author":"S Dogan","year":"2012","unstructured":"Dogan S, Shen R, Ang DC, Johnson ML, D\u2019Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18:6169\u201377.","journal-title":"Clin Cancer Res"},{"key":"3877_CR3","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jtho.2019.01.020","volume":"14","author":"B El Osta","year":"2019","unstructured":"El Osta B, Behera M, Kim S, Berry LD, Sica G, Pillai RN, et al. Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience. J Thorac Oncol. 2019;14:876\u201389.","journal-title":"J Thorac Oncol"},{"key":"3877_CR4","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020;80:2969\u201374.","journal-title":"Cancer Res"},{"key":"3877_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/JTO.0000000000000432","volume":"10","author":"HA Yu","year":"2015","unstructured":"Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, et al. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas. J Thorac Oncol. 2015;10:431\u20137.","journal-title":"J Thorac Oncol"},{"key":"3877_CR6","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","volume":"15","author":"JM Ostrem","year":"2016","unstructured":"Ostrem JM, Shokat KM. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov. 2016;15:771\u201385.","journal-title":"Nat Rev Drug Discov"},{"key":"3877_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351.","journal-title":"Nature"},{"key":"3877_CR8","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, et al. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discov. 2016;6:316\u201329.","journal-title":"Cancer Discov"},{"key":"3877_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018;172:578\u2013589.e517.","journal-title":"Cell"},{"key":"3877_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401:733\u201346.","journal-title":"Lancet"},{"key":"3877_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0140-6736(25)00866-9","volume":"406","author":"F Barlesi","year":"2025","unstructured":"Barlesi F, Yao W, Duruisseaux M, Doucet L, Martinez AA, Gregorc V, et al. Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial. Lancet. 2025;406:615\u201326.","journal-title":"Lancet"},{"key":"3877_CR12","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31:1056\u201364.","journal-title":"Ann Oncol"},{"key":"3877_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378:113\u201325.","journal-title":"N Engl J Med"},{"key":"3877_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez M, Rajaram S, Steininger RJ, Osipchuk D, Roth MA, Morinishi LS, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun. 2016;7:10690.","journal-title":"Nat Commun"},{"key":"3877_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","volume":"7","author":"JJ Lin","year":"2017","unstructured":"Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov. 2017;7:137\u201355.","journal-title":"Cancer Discov"},{"key":"3877_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga T, Suda K, Fujino T, Ohara S, Hamada A, Nishino M, et al. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. J Thorac Oncol. 2021;16:1321\u201332.","journal-title":"J Thorac Oncol"},{"key":"3877_CR17","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired Resistance to KRAS(G12C) Inhibition in Cancer. N Engl J Med. 2021;384:2382\u201393.","journal-title":"N Engl J Med"},{"key":"3877_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021;599:679\u201383.","journal-title":"Nature"},{"key":"3877_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, et al. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577:421\u20135.","journal-title":"Nature"},{"key":"3877_CR20","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.23.00046","volume":"41","author":"MV Negrao","year":"2023","unstructured":"Negrao MV, Spira AI, Heist RS, Janne PA, Pacheco JM, Weiss J, et al. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. J Clin Oncol. 2023;41:4472\u20137.","journal-title":"J Clin Oncol"},{"key":"3877_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115301","volume":"219","author":"M Wislez","year":"2025","unstructured":"Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, et al. Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study. Eur J Cancer. 2025;219:115301.","journal-title":"Eur J Cancer"},{"key":"3877_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101578","volume":"5","author":"K Fukuda","year":"2024","unstructured":"Fukuda K, Takeuchi S, Arai S, Nanjo S, Sato S, Kotani H, et al. Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. Cell Rep Med. 2024;5:101578.","journal-title":"Cell Rep Med"},{"key":"3877_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin J, Engstrom LD, Hargis L, Calinisan A, Aranda R, Briere DM, et al. The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020;10:54\u201371.","journal-title":"Cancer Discov"},{"key":"3877_CR24","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","volume":"26","author":"Y Adachi","year":"2020","unstructured":"Adachi Y, Ito K, Hayashi Y, Kimura R, Tan TZ, Yamaguchi R, et al. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2020;26:5962\u201373.","journal-title":"Clin Cancer Res"},{"key":"3877_CR25","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ccell.2024.01.012","volume":"42","author":"X Tong","year":"2024","unstructured":"Tong X, Patel AS, Kim E, Li H, Chen Y, Li S, et al. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer. Cancer Cell. 2024;42:413\u2013428.e417.","journal-title":"Cancer Cell"},{"key":"3877_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","volume":"15","author":"A Singh","year":"2009","unstructured":"Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15:489\u2013500.","journal-title":"Cancer Cell"},{"key":"3877_CR27","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s43018-023-00575-2","volume":"4","author":"Y Adachi","year":"2023","unstructured":"Adachi Y, Kimura R, Hirade K, Yanase S, Nishioka Y, Kasuga N, et al. Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS. Nat Cancer. 2023;4:829\u201343.","journal-title":"Nat Cancer"},{"key":"3877_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2012.02.053","volume":"149","author":"JS Duncan","year":"2012","unstructured":"Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 2012;149:307\u201321.","journal-title":"Cell"},{"key":"3877_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1158\/2159-8290.CD-15-1377","volume":"6","author":"H Kitai","year":"2016","unstructured":"Kitai H, Ebi H, Tomida S, Floros KV, Kotani H, Adachi Y, et al. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer. Cancer Discov. 2016;6:754\u201369.","journal-title":"Cancer Discov"},{"key":"3877_CR30","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","volume":"26","author":"MB Ryan","year":"2020","unstructured":"Ryan MB, Fece de la Cruz F, Phat S, Myers DT, Wong E, Shahzade HA, et al. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS(G12C) Inhibition. Clin Cancer Res. 2020;26:1633\u201343.","journal-title":"Clin Cancer Res"},{"key":"3877_CR31","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger R, Uboha NV, Pelster MS, Bekaii-Saab TS, Barve M, Saltzman J, et al. Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer. Cancer Discov. 2024;14:982\u201393.","journal-title":"Cancer Discov"},{"key":"3877_CR32","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;389:2125\u201339.","journal-title":"N Engl J Med"},{"key":"3877_CR33","doi-asserted-by":"publisher","first-page":"6528","DOI":"10.1073\/pnas.85.17.6528","volume":"85","author":"M Shoyab","year":"1988","unstructured":"Shoyab M, McDonald VL, Bradley JG, Todaro GJ. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA. 1988;85:6528\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3877_CR34","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1182\/bloodadvances.2018017343","volume":"2","author":"SG Holtan","year":"2018","unstructured":"Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, et al. Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302\/0802. Blood Adv. 2018;2:1882\u20138.","journal-title":"Blood Adv"},{"key":"3877_CR35","first-page":"119","volume":"1816","author":"B Busser","year":"2011","unstructured":"Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta. 2011;1816:119\u201331.","journal-title":"Biochim Biophys Acta"},{"key":"3877_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2007.01.015","volume":"254","author":"C Berasain","year":"2007","unstructured":"Berasain C, Castillo J, Perugorria MJ, Prieto J, Avila MA. Amphiregulin: a new growth factor in hepatocarcinogenesis. Cancer Lett. 2007;254:30\u201341.","journal-title":"Cancer Lett"},{"key":"3877_CR37","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jtho.2020.01.001","volume":"15","author":"S Arai","year":"2020","unstructured":"Arai S, Takeuchi S, Fukuda K, Taniguchi H, Nishiyama A, Tanimoto A, et al. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. J Thorac Oncol. 2020;15:752\u201365.","journal-title":"J Thorac Oncol"},{"key":"3877_CR38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.cellsig.2008.10.003","volume":"21","author":"NE Willmarth","year":"2009","unstructured":"Willmarth NE, Baillo A, Dziubinski ML, Wilson K, Riese DJ 2nd, Ethier SP. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin\/EGFR autocrine loop. Cell Signal. 2009;21:212\u20139.","journal-title":"Cell Signal"},{"key":"3877_CR39","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1021\/bi801771g","volume":"48","author":"A Baldys","year":"2009","unstructured":"Baldys A, Gooz M, Morinelli TA, Lee MH, Raymond JR Jr., Luttrell LM, et al. Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry. 2009;48:1462\u201373.","journal-title":"Biochemistry"},{"key":"3877_CR40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/1535-7163.MCT-16-0522","volume":"16","author":"S Nanjo","year":"2017","unstructured":"Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, et al. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Mol Cancer Ther. 2017;16:506\u201315.","journal-title":"Mol Cancer Ther"},{"key":"3877_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/vde.12787","volume":"30","author":"M Mazzei","year":"2019","unstructured":"Mazzei M, Vascellari M, Zanardello C, Melchiotti E, Vannini S, Forzan M, et al. Quantitative real time polymerase chain reaction (qRT-PCR) and RNAscope in situ hybridization (RNA-ISH) as effective tools to diagnose feline herpesvirus-1-associated dermatitis. Vet Dermatol. 2019;30:491\u2013e147.","journal-title":"Vet Dermatol"},{"key":"3877_CR42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.humpath.2015.09.009","volume":"47","author":"V Bingham","year":"2016","unstructured":"Bingham V, Ong CW, James J, Maxwell P, Waugh D, Salto-Tellez M, et al. PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry. Hum Pathol. 2016;47:95\u2013103.","journal-title":"Hum Pathol"},{"key":"3877_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jmoldx.2012.10.003","volume":"15","author":"Z Wang","year":"2013","unstructured":"Wang Z, Portier BP, Gruver AM, Bui S, Wang H, Su N, et al. Automated quantitative RNA in situ hybridization for resolution of equivocal and heterogeneous ERBB2 (HER2) status in invasive breast carcinoma. J Mol Diagn. 2013;15:210\u20139.","journal-title":"J Mol Diagn"},{"key":"3877_CR44","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1002\/jcb.25606","volume":"117","author":"CM Anderson","year":"2016","unstructured":"Anderson CM, Zhang B, Miller M, Butko E, Wu X, Laver T, et al. Fully Automated RNAscope In Situ Hybridization Assays for Formalin-Fixed Paraffin-Embedded Cells and Tissues. J Cell Biochem. 2016;117:2201\u20138.","journal-title":"J Cell Biochem"},{"key":"3877_CR45","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/wdev.170","volume":"4","author":"I Gaspar","year":"2015","unstructured":"Gaspar I, Ephrussi A. Strength in numbers: quantitative single-molecule RNA detection assays. Wiley Interdiscip Rev Dev Biol. 2015;4:135\u201350.","journal-title":"Wiley Interdiscip Rev Dev Biol"},{"key":"3877_CR46","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.humpath.2018.07.025","volume":"82","author":"JD Coppock","year":"2018","unstructured":"Coppock JD, Volaric AK, Mills AM, Gru AA. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas. Hum Pathol. 2018;82:282\u20138.","journal-title":"Hum Pathol"},{"key":"3877_CR47","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1097\/PAI.0000000000000595","volume":"26","author":"MM Gafeer","year":"2018","unstructured":"Gafeer MM, Hosny Mohammed K, Ormenisan-Gherasim C, Choudhary F, Siddiqui MT, Cohen C. Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization. Appl Immunohistochem Mol Morphol. 2018;26:e86\u2013e90.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"3877_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jtho.2018.09.025","volume":"14","author":"MP Humphries","year":"2019","unstructured":"Humphries MP, McQuaid S, Craig SG, Bingham V, Maxwell P, Maurya M, et al. Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities. J Thorac Oncol. 2019;14:45\u201353.","journal-title":"J Thorac Oncol"},{"key":"3877_CR49","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4:1046\u201361.","journal-title":"Cancer Discov"},{"key":"3877_CR50","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016;22:5130\u201340.","journal-title":"Clin Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03877-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03877-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:01:38Z","timestamp":1785189698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03877-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":50,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2026,8,18]]}},"alternative-id":["3877"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03877-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shigeki Nanjo has received speaker fees from Chugai Pharmaceutical, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Taiho Pharmaceutical, and Kyowa Kirin. Seiji Yano has received research grants from Chugai Pharmaceutical and Eli Lilly Japan and honoraria from Amgen, Chugai Pharmaceutical, AstraZeneca, and Eli Lilly Japan. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}